Sionna Therapeutics, Inc. (SION) Price & Analysis

Compare

25 Followers

SION Stock Chart & Stats

$34.57

$0.55(1.26%)

At close: Feb 03 4:00 PM EST

$34.57

$0.55(1.26%)

Day’s Range― - ―

52-Week Range$7.26 - $45.00

Previous CloseN/A

Volume33.51K

Average Volume (3M)254.91K

Market Cap

$1.56B

Enterprise Value$1.49B

Total Cash (Recent Filing)$235.88M

Total Debt (Recent Filing)$8.68M

Price to Earnings (P/E)―

Beta1.02

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding44,998,074

10 Day Avg. Volume146,250

30 Day Avg. Volume254,913

Financial Highlights & Ratios

PEG Ratio-0.64

Price to Book (P/B)5.36

Price to Sales (P/S)0.00

P/FCF Ratio-24.66

Enterprise Value/Market Cap0.96

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-19.83

Forecast

1Y Price Target

$51.17

Price Target Upside48.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Proof-of-conceptPhase 2a crossover design targets a clinically meaningful sweat chloride reduction without new safety signals, which would validate the NBD1 stabilization approach and materially lower development risk.

Combination Compatibility And TolerabilityDrug–drug interaction testing and pharmacokinetic and safety data indicate the candidate can be combined with standard CF therapy and achieves intended exposure at low doses, supporting both add-on and standalone development paths.

Translational Assay ValidationCalibration of the company's CF HBE assay to the industry standard creates a translational tool that guides dose selection and increases confidence in the probability of clinical success for NBD1 stabilizers.

Bears Say

Funding RiskHigh cash burn and a limited cash runway create financing risk and raise the likelihood of future capital raises that could dilute existing shareholders.

Limited Trial Power And Endpoint RelianceSmall patient cohorts and short treatment durations in the Phase 2a study may hamper detection of lung function changes, making trial outcomes heavily dependent on a single biomarker measure.

Rising Operating CostsHigher selling, general, and administrative expenses driven by personnel-related costs increase pressure on operating margins and heighten the need for additional funds.

Sionna Therapeutics, Inc. News

Sionna Therapeutics price target raised to $50 from $45 at Guggenheim

Guggenheim raised the firm’s price target on Sionna Therapeutics (SION) to $50 from $45 and keeps a Buy...

3d ago

SION

Sionna Therapeutics files automatic mixed securities shelf

08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

4d ago

SION

Sionna Therapeutics files automatic mixed securities shelf

08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

4d ago

SION

Sionna Therapeutics files automatic mixed securities shelf

08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

4d ago

SION

Sionna Therapeutics reports Q4 EPS (46c), consensus (55c)

Cash, cash equivalents and marketable securities totaled$310.3 millionas of December 31, 2025. Sionna expects its current cash position...

4d ago

SION

Sionna Therapeutics initiated with an Outperform at Citizens

Citizens initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $63 price target Sionna is developing...

10d ago

SION

Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target

Analyst Kambiz Yazdi from BTIG maintained a Buy rating on Sionna Therapeutics, Inc. and keeping the price target...

2M ago

SION

Sionna Therapeutics price target raised to $58 from $50 at BTIG

BTIG raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and keeps a Buy...

2M ago

SION

VRTX

Sionna Therapeutics price target raised to $58 from $50 at BTIG

BTIG analyst Kambiz Yazdi raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and...

2M ago

SION

Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AME

Sionna Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital analyst Cory Jubinville initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $60 price...

2M ago

SION

Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis

Cory Jubinville, PhD, an analyst from LifeSci Capital, has initiated a new Buy rating on Sionna Therapeutics, Inc....

2M ago

SION

BTIG Assigns Buy Rating to Sionna Therapeutics, Citing Innovative Cystic Fibrosis Therapies and Strong Market Potential

, an analyst from BTIG, has initiated a new Buy rating on Sionna Therapeutics, Inc. (SION). BTIG has...

4M ago

SION

Sionna Therapeutics: Promising Developments and Strategic Advancements Boost Price Target

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on SION stock, giving a Buy rating on November...

4M ago

SION

SION FAQ

What was Sionna Therapeutics, Inc.’s price range in the past 12 months?

Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $45.00 in the past 12 months.

What is Sionna Therapeutics, Inc.’s market cap?

Sionna Therapeutics, Inc.’s market cap is $1.56B.

When is Sionna Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Sionna Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Sionna Therapeutics, Inc. overvalued?

According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sionna Therapeutics, Inc. pay dividends?

Sionna Therapeutics, Inc. does not currently pay dividends.

What is Sionna Therapeutics, Inc.’s EPS estimate?

Sionna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sionna Therapeutics, Inc. have?

Sionna Therapeutics, Inc. has 44,998,074 shares outstanding.

What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?

Currently, no hedge funds are holding shares in SION

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sionna Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-28.07%

Trailing 12-Months

Asset Growth

71.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Sionna Therapeutics, Inc. (SION) Earnings & Revenues

Historic Earnings Reports

SION Stock 12 Month Forecast

Average Price Target

$51.17

▲(48.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","64":"$64","22.75":"$22.8","36.5":"$36.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$63.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,22.75,36.5,50.25,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.92,36.15692307692308,38.393846153846155,40.63076923076923,42.86769230769231,45.104615384615386,47.34153846153846,49.57846153846154,51.815384615384616,54.05230769230769,56.28923076923077,58.526153846153846,60.76307692307692,{"y":63,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.92,35.24692307692308,36.573846153846155,37.900769230769235,39.22769230769231,40.55461538461539,41.88153846153846,43.20846153846154,44.535384615384615,45.862307692307695,47.18923076923077,48.51615384615385,49.84307692307692,{"y":51.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.92,33.15692307692308,32.393846153846155,31.630769230769232,30.86769230769231,30.104615384615386,29.341538461538462,28.57846153846154,27.815384615384616,27.052307692307693,26.28923076923077,25.526153846153846,24.763076923076923,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.24,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.92,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >